Bioblast


Also found in: Medical.

Bi´o`blast


n.1.(Biol.) Same as Bioplast.
References in periodicals archive ?
Rosskamp, a pediatric endocrinologist with more than 15 years of experience in clinical medicine, is a member of the board of directors of Bioblast Pharma in Tel Aviv, Israel.
BioBlast Pharma declared that it has named Theresa (Terri) Stevens to the newly-made designation of Chief Corporate Development Officer (CCDO).
Colin Foster, President and Chief Executive Officer of BioBlast said, "I'm thrilled to have Terri join our executive team given her impressive global experience in corporate strategy, M&A, and business development.
In a controlled laboratory setting, oxygen-deficient conditions, third-party testing proved that EcoSure BioBlast fibers biodegrade at least 12 times faster than traditional polyester and petroleum-based fibers over a one-year period.
EcoSure BioBlast fibers have been under development for two years and just completed 365 days of testing with Eden Research Lab, a third-party vendor in New Mexico.
Biotechnology company BioBlast Pharma (NasdaqGM:ORPN) reported on Thursday the receipt of orphan drug designation from the European Commission for Cabaletta for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD).
BioBLAST (Better Learning through Adventure, Simulations and Telecommunication) is an "educational environment" -- built on a framework of scientific inquiry and rich content representation -- delivered on a CD-ROM.
Product Pipeline Review - 2015', provides an overview of the Bioblast Pharma Ltd.
Biotechnology company BioBlast Pharma (NasdaqGM:ORPN) reported on Monday the launch of a Phase 3 pivotal study of Cabaletta (trehalose) in Oculopharyngeal Muscular Dystrophy (OPMD) in the US and Canada.
As compared to Alcobra, which is based on creating a single molecule, BioBlast Pharma is creating a platform of products for rare and ultra-rare genetic ailments.
Biotechnology company BioBlast Pharma (NasdaqGM:ORPN) reported on Tuesday the receipt of a notice of allowance from the US Patent and Trademark Office (USPTO) for the composition and method of Cabaletta for the treatment of oculopharyngeal muscular dystrophy (OPMD).
Dalia Megiddo, MD, chief executive officer of BioBlast, said, 'This patent covers the significant innovations we have made in the delivery of therapeutic proteins into mitochondria.